| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4229820 | Journal of the American College of Radiology | 2016 | 5 Pages |
Abstract
Reimbursement levels, payor mix, scanner location, and radiopharmaceutical costs are all critical, variable factors for modeling the financial viability of I-123 ioflupane imaging and, by extrapolation, future radiopharmaceuticals.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Matthew F. MD, Natalie A. BS, CNMT, Phillip H. MD, PhD,